News
BMS inks drug discovery deal with Schrödinger
Bristol Myers Squibb will pay $55m upfront to American life sciences company Schrödinger to access its drug discovery platform.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Bristol Myers Squibb will pay $55m upfront to American life sciences company Schrödinger to access its drug discovery platform.